Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026

PUBLISHED: March 1, 2026

PAGES: 800+ Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Benchmark Acquisition Strategies Across the Global Life Sciences Industry

The Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026 report provides a comprehensive analysis of acquisition activity across the global life sciences sector. Designed for corporate development, business development, investment, and strategy professionals, the report delivers detailed insight into how companies structure mergers and acquisitions and negotiate the financial terms behind these transactions.

Fully revised and updated, the report analyzes 2,500+ M&A agreements announced between January 2021 and March 2026, offering an extensive view of acquisition activity across pharmaceutical, biotechnology, and diagnostics companies.

Each transaction links to a detailed online deal record and, where available, the original contract documents filed with regulators. By combining comprehensive deal data, financial benchmarking, and contract access, the report provides valuable intelligence for evaluating acquisition opportunities, benchmarking transaction values, and understanding industry consolidation strategies.

Key Benefits

Save Significant Research Time

Access over 2,500 M&A deals in one consolidated resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

Benchmark Acquisition Structures and Valuations

Understand how pharmaceutical, biotechnology, and diagnostics companies structure acquisitions, including cash transactions, equity deals, and hybrid structures.

Analyze Transaction Values with Confidence

Review disclosed deal values and financial terms to benchmark acquisition prices and transaction structures across comparable deals.

Access Real Contract Documents

Where available, explore SEC-filed merger and acquisition agreements, providing insight into the detailed contractual provisions behind real transactions.

Identify the Most Active Acquirers

Discover which companies are leading consolidation activity and analyze their acquisition strategies.

Track Industry Consolidation Trends

Analyze M&A activity across companies, therapeutic areas, and technology sectors to understand how the life sciences industry is evolving.

What's Included in the Report

Analysis of M&A dealmaking trends since 2021

Overview of merger and acquisition transaction structures

Review of leading acquisitions by disclosed deal value

Profiles of the most active acquirers and dealmakers

Detailed analysis of deals by company, therapeutic area, technology type, and industry segment

A comprehensive directory of M&A transactions announced since 2021

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual merger and acquisition contracts, the report enables users to evaluate key transaction provisions such as:

Asset and company acquisition structures
Purchase price and payment mechanisms
Intellectual property transfer provisions
Earn-out structures and contingent payments
Operational integration responsibilities
Transaction closing conditions and termination clauses
Access to real agreements provides insight into the detailed terms negotiated between companies-information rarely disclosed in press releases or traditional deal databases.
Why This Report Matters
Mergers and acquisitions are a critical strategy for pharmaceutical and biotechnology companies seeking to expand pipelines, acquire innovative technologies, and accelerate growth. The life sciences industry experiences significant M&A activity each year as companies pursue strategic acquisitions to strengthen their portfolios and capabilities.
By combining comprehensive acquisition data, transaction benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, understand industry consolidation trends, and negotiate more effectively.

Product Code: CP2051

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2021
- 2.3.1. M&A dealmaking by year since 2021
- 2.3.2. M&A dealmaking by industry sector since 2021
- 2.3.3. M&A dealmaking by therapy area since 2021
- 2.3.4. M&A dealmaking by most active company since 2021
2.4. Key M&A trends
2.5. Option to acquire the new acquisition?
2.6. When M&A can be useful
2.7. Attributes of M&A deals
- 2.7.1. M&A as an alternative to IPO
2.8. Partnering deals with M&A component
- 2.8.1. Partnering as a precursor to M&A
- 2.8.2. Equity as part of partnering deal
- 2.8.3. Conversion of partnership to acquisition
- 2.8.4. But M&A is not always the route followed
2.9. Big pharma mega mergers - are we at the end of the road?
- 2.9.1. Growth of Johnson & Johnson through M&A
- 2.9.2. Growth of Novartis through M&A
2.10. Accessing innovation through M&A
- 2.10.1. Big pharma acquisitions of small companies
- 2.10.2. Medium and small biopharma - use of M&A
- 2.10.3. Using M&A to build a company
- 2.10.4. Emergence of biotech-biotech mergers
2.11. The emerging role of private equity in M&A
2.12. Implementing M&A transactions
2.13. Joint ventures as alternative to M&A
2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.4. Acquisition as part of a wider alliance agreement
3.5. Merger agreements

Chapter 4 - Leading M&A deals

4.1. Introduction
4.2. Top M&A deals by value

Chapter 5 - Top 25 most active M&A dealmakers

5.1. Introduction
5.2. Top 25 most active M&A dealmakers

Chapter 6 - M&A contract directory since 2021

6.1. Introduction
6.2. M&A deals with contracts since 2021
Deal Directory
Deal Directory - M&A deals by company A-Z
Deal Directory - M&A deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Definition of merger and acquisition
Figure 2: Trends in M&A deal announcements
Figure 3: M&A deals by industry sector
Figure 4: M&A deals by therapy area
Figure 5: Top 50 most active M&A dealmakers
Figure 6: Key recent M&A trends
Figure 7: Situations where M&A can prove useful
Figure 8: Recent partnering deals involving equity participation in the licensor
Figure 9: Equity investments converting to acquisitions
Figure 10: Issues in implementing M&A agreements
Figure 11: Future trends in M&A in biopharma
Figure 12: Components of the acquisition deal structure
Figure 13: Components of the merger deal structure
Figure 14: Top M&A deals by value
Figure 15: Most active M&A dealmakers